IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
IASO Biotherapeutics
Private
Chinese cell therapy company developing BCMA-targeted CAR-T therapies, led by equecabtagene autoleucel (CT103A) for relapsed/refractory multiple myeloma, with an in vivo CAR-T pipeline.
Company Info
Sector:Cell Therapy / CAR-T
Headquarters:Nanjing, China
Founded:2018
Website:www.iasobio.com/
Funding Round:Series C
Total Funding:~$200M
Funding & Investor Relations
Notable Investors
- Umoja Biopharma (partner)
- Undisclosed
IPO Outlook / Plans
Private; no announced IPO timeline
Upcoming Milestones & Key Dates
2026-Q4
Trial Milestone
First-in-human study initiation for IASO208